RUO monalizumab是一種阻斷抗體,可防止表達(dá)HLA-E的腫瘤細(xì)胞對CD 8 + T細(xì)胞和NK細(xì)胞的抑制。通過同時作用于先天免疫和適應(yīng)性免疫,monalizumab可以重新建立廣泛的抗腫瘤反應(yīng)。 Monalizumab生物仿制藥-超低內(nèi)毒素該產(chǎn)品同種型對照:Bulk Human IgG4 Isotype Control (IB4) [ICH2257] 緩沖液:ICH3002 濃度:5mg/ml 純度:>95% by SDS-PAGE 內(nèi)毒素:≤ 0.1 EU/mg as determined by the LAL method 制劑:Sterile, preservative-free, solution in PBS. BSA and Azide free.